The global varicella live vaccine market was valued at $2,714 million in 2018, and is expected to reach $4,222 million by 2026, registering a CAGR of 5.7% from 2019 to 2026

Thursday, November 28, 2019 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Nov. 28, 2019 /PRNewswire/ --

Varicella Live Vaccine Market by Product (Monovalent Varicella Vaccine and Combination Varicella Vaccine), Application (Chickenpox Immunization, Herpes Zoster Immunization, and MMRV Immunization), and Provider (Public Provider, and Private Provider): Global Opportunity Analysis and Industry Forecast, 2018-2026

Read the full report:

The global varicella live vaccine market was valued at $2,714 million in 2018, and is expected to reach $4,222 million by 2026, registering a CAGR of 5.7% from 2019 to 2026. Varicella live vaccines contain an attenuated form of the varicella zoster virus. These vaccines help build immunity against varicella zoster virus as the infection can cause serious diseases such as chicken pox and herpes zoster. Immunization against these diseases is necessary as chicken pox can lead to serious complications such as bacterial infections of the skin and soft tissues in children. Moreover, herpes zoster is another painful condition that is caused by the reactivation of the varicella zoster virus after primary infection. Therefore, immunization with varicella live vaccine serves as an effective method for prevention of these diseases. These vaccines are mainly of two types such as monovalent and combination. The monovalent vaccines contain a single strain of a single antigen such as varicella live vaccines, contain weakened strain of varicella zoster virus. However, the combination varicella vaccines contain multiple strains of infectious agents. The factors that boost the growth of the varicella live vaccine market include surge in immunization programs across the globe. Moreover, rise in awareness related to the use of varicella live vaccines and surge in adoption of varicella vaccination worldwide also fuel the growth of the varicella live vaccine market. However, high monetary inputs associated with the production of the products restrict the growth of the market. Conversely, growth potential in emerging economies is expected to create lucrative opportunities for the market during the forecast period. The global varicella live vaccine market is segmented based on product, application, provider, and region. On the basis of product, the market is bifurcated into monovalent varicella vaccine and combination varicella vaccine. By application, it is divided into chicken pox immunization, herpes zoster immunization and measles, mumps, rubella, and varicella (MMRV) immunization. On the basis of provider, it is segmented into public provider and private provider. Based on region, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, the UK, Italy, Spain, France, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and, rest of Asia-Pacific) and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA). KEY BENEFITS FOR STAKEHOLDERS • This report entails a detailed quantitative analysis along with the current global varicella live vaccine market trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessment. • The market size and estimations are based on a comprehensive analysis of key developments in the industry. • A qualitative analysis based on innovative products facilitates strategic business planning. • The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market Key Market Segments • By Product o Monovalent Varicella Vaccine o Combination Varicella Vaccine • By Application o Chickenpox immunization o Herpes Zoster Immunization o Mumps, Measles, Rubella and Varicella (MMRV) Immunization • By Provider o Public Provider o Private Provider • By Region o North America - U.S. - Canada - Mexico o Europe - Germany - France - UK - Italy - Spain - Rest of Europe o Asia-Pacific - Japan - China - India - Australia - South Korea - Rest of Asia-Pacific o LAMEA - Brazil - Saudi Arabia - South Africa - Rest of LAMEA List of key players profiled in the report: • Bio-Med Pvt. Limited • Changchun BCHT Biotechnology Co. Ltd. • Emcure Pharmaceuticals Limited • GlaxoSmithKline plc • Green Cross Holdings (GC Pharma) • Merck & Co. Inc. • Mitsubishi Chemical Holdings Corporation (Mitsubishi Tanabe Pharma Corporation) • Novo Medi Sciences Pvt. Ltd. • Sanofi • Takeda Pharmaceutical Company Limited LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request) • VHB Life Sciences • Wockhardt Ltd.Read the full report: About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: US: (339)-368-6001 Intl: +1 339-368-6001

Cision View original content:

SOURCE Reportlinker

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z



Premium Membership Benefits

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store